Results 51 to 60 of about 5,803 (182)

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Informatics in Medicine Unlocked, 2021
Background: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results ...
Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh   +3 more
doaj   +1 more source

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.

, 2014
About 150,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). HCV infection can lead to liver cirrhosis, hepatocellular carcinoma and death.
CASTALDO, GIUSEPPE, BUONOMO, ANTONIO RICCARDO, F. Borgia, GENTILE, Ivan, BORGIA, GUGLIELMO   +4 more
core   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: A and clinical perspective

, 2016
Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of care.
Serste, Thomas, Nkuize, Marcel, Buset, Michel, Mulkay, Jean-Pierre   +3 more
core   +1 more source

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Mohammed M. El-Kabany, Negin L. Esmailzadeh, Gina Choi, Busuttil, Ronald W, Han, Steven-Huy B, Durazo, Francisco A, Samantha D. Ramirez, Esmailzadeh, Negin L, Sherona N. Bau, Michelle H. Mai, Saab, Sammy, Kang, Susan, Grotts, Jonathan, Choi, Gina, Caterina A. Kachadoorian, Bau, Sherona N, Ramirez, Samantha D, Fong, Tiffany M, Ronald W. Busuttil, Kachadoorian, Caterina A, Susan Kang, Jimenez, Melissa A, Steven-Huy B. Han, El-Kabany, Mohammed M, Sammy Saab, Tiffany M. Fong, Jonathan Grotts, Francisco A. Durazo, Mai, Michelle H, Justin Rheem, Melissa A. Jimenez, Rheem, Justin   +31 more
core   +1 more source

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study

Caspian Journal of Internal Medicine, 2020
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting.
Heidar Sharafi, Seyed Hoda Alavian, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Mehri Nikbin, Seyed Moayed Alavian   +5 more
doaj  

Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease

The Korean Journal of Gastroenterology, 2016
Article: Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease (Gastroenterology 2015;149:649-659)
Woo Jin Chung
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Interferon and ribavirin have been used as therapeutic agents for chronic hepatitis C infection or C-compensated cirrhosis in the conventional treatment.
Sachiko Omotani, Toshihiko Ishizaka, Miki Inoue, Koji Nishida, Yukako Yasui, Yasutoshi Hatsuda, Junji Mukai, Michiaki Myotoku   +7 more
doaj   +1 more source